Alzheimer’s Trial Setback: Recent discussions on X about Novo Nordisk (NVO) have centered on the disappointing results of its Phase 3 Alzheimer’s trial for semaglutide. Posts highlight a sharp decline in share price, with some noting a drop of over 10% following the news. Investors had hoped for a new application beyond diabetes and obesity, but the trial’s failure has shaken confidence.
Mixed Analyst Views: Conversations on X also reveal a split among analysts regarding NVO’s future. Some posts mention downgrades to underweight with reduced price targets, while others point to upgrades and optimism about the company’s pipeline. The diversity of opinions keeps the stock a hot topic among traders.
Potential Reversal Buzz: Despite the setback, a few discussions on X suggest that NVO might be nearing a reversal point after its recent correction. There’s cautious optimism about a breakout, though many remain wary of overhead resistance. The stock continues to draw attention as investors weigh risks and opportunities.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Congressional Stock Trading
Members of Congress have traded $NVO stock 14 times in the past 6 months. Of those trades, 10 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 7 times. They made 3 purchases worth up to $45,000 on 10/30, 09/11, 06/09 and 4 sales worth up to $60,000 on 10/31, 10/30, 08/04, 07/10.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $80,000 on 10/15, 08/28, 08/19 and 0 sales.
- REPRESENTATIVE SCOTT FRANKLIN has traded it 4 times. They made 4 purchases worth up to $95,000 on 08/04 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Novo Nordisk Hedge Fund Activity
We have seen 655 institutional investors add shares of Novo Nordisk stock to their portfolio, and 908 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 17,659,339 shares (-93.5%) from their portfolio in Q3 2025, for an estimated $979,916,721
- FRANKLIN RESOURCES INC added 13,658,867 shares (+4190.8%) to their portfolio in Q3 2025, for an estimated $757,930,529
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 10,005,216 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $555,189,435
- CLEARBRIDGE INVESTMENTS, LLC removed 7,332,020 shares (-89.2%) from their portfolio in Q3 2025, for an estimated $406,853,789
- SUSTAINABLE GROWTH ADVISERS, LP removed 6,187,063 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $343,320,125
- CAPITAL INTERNATIONAL INVESTORS added 6,092,192 shares (+52.4%) to their portfolio in Q3 2025, for an estimated $338,055,734
- BOSTON PARTNERS added 5,571,017 shares (+inf%) to their portfolio in Q3 2025, for an estimated $309,135,733
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 11/28/2025
- Jefferies issued a "Underperform" rating on 10/27/2025
- Morgan Stanley issued a "Underweight" rating on 09/29/2025
- Berenberg issued a "Buy" rating on 09/17/2025
- TD Cowen issued a "Buy" rating on 08/19/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 5 analysts offer price targets for $NVO in the last 6 months, with a median target of $54.0.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $54.0 on 11/28/2025
- Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025
- Rajesh Kumar from HSBC set a target price of $70.0 on 10/02/2025
- Thibault Boutherin from Morgan Stanley set a target price of $47.0 on 09/29/2025
- Michael Nedelcovych from TD Cowen set a target price of $70.0 on 08/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
